BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company's lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3, currently being evaluated in the treatment of metastatic bladder cancer.
Market
Pharmaceuticals
Location
San Ramon,
California,
USA
Coinvestors
HealthCap, Life Sciences Partners, Sofinnova Ventures, Tekla Capital Management, Ysios Capital